RxDoctor Payments Data

Jason Davis, DO

General Practice · Davenport, IANPI 1588662050

Payments from drug & device makers

$481in general payments, 2019–2025

Across 24 payments — averaging $20.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$117
  • Novo Nordisk$75
  • Lilly USA, LLC$47
  • Dexcom, Inc.$39
  • Phathom Pharmaceuticals, Inc.$36
  • AstraZeneca$34
  • plus $134 from 7 others

What the payments were for

  • Food & beverage$38279%
  • Education$9921%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$481 in reported general payments places this provider in the 60th percentile of 882 general practice providers in Iowa.

See all general practice providers in Iowa

Medicare billing

Part B allowed, 2024
$112,396
Medicare patients
326
Services billed
1,459

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin152$181,899
OzempicSemaglutide121$156,052
EliquisApixaban65$71,230
MounjaroTirzepatide23$31,339
RybelsusSemaglutide19$23,775
Lantus SolostarInsulin Glargine,hum.Rec.Anlog94$17,855
XareltoRivaroxaban24$17,147
Breo ElliptaFluticasone/Vilanterol26$14,417
JanuviaSitagliptin Phosphate14$14,278
Tresiba Flextouch U-100Insulin Degludec11$13,979
Combivent RespimatIpratropium/Albuterol Sulfate18$13,521
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$13,084
TrulicityDulaglutide13$12,653
Humalog Kwikpen U-100Insulin Lispro30$8,447
SymbicortBudesonide/Formoterol Fumarate13$4,596

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance, Combivent Respimat$27$195,420170 claims
Novo NordiskOzempic, Rybelsus$75$179,827140 claims
Lilly USA, LLCMounjaro, Trulicity$47$43,99136 claims
Johnson & JohnsonXarelto$12$17,14724 claims
AstraZenecaSymbicort$34$4,59613 claims
Sanofi-aventis U.S. LLCLantus$22$2,96712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 882 general practice providers in Iowa.

Other general practice in Davenport

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →